

Neoadjuvant	Post-Neoadjuvant	Adjuvant	Metastatic
<div>EA1211 (DIRECT) HER2+ Stage IIa-IIlc</div> <div>S2212 (SCARLET) TNBC T2-4/N0/M0, or T1-3/N1-2/M0</div> <div>S2206 HR+/HER2- Stage II or III</div>	<div>A012103 (OptimICE-PCR) TNBC Early-Stage, pCR post pre-op chemo + pembrolizumab</div>	<div>CCTG MA.39 HR+/HER2- Low risk; Node positive</div> <div>NRG-BR007 (DEBRA) HR+/HER2- pT1(<=2cm) pN0M0</div> <div>NRG-BR009 (OFFSET) HR+/HER2- pT1-3/N0-1/M0, Oncotype Recurrence Score ≤ 25, Premenopausal patients</div> <div>A012301 (LoTam) HR+/HER2- Early-stage, Low molecular risk, Resected tumor ≤3cm and N0, Postmenopausal pts</div> <div>NRG-BR008 (HERO) HER2+ Low risk, N0M0</div>	<div>EAY191 (ComboMATCH) <div>Sub-study: EAY191-A3 (RAS-mutant)</div><div>Sub-study: EAY191-E5 (KRAS G12C mutation)</div></div>

NCTN Breast Cancer Trials (Open as of 5/15/2025)

Protocol Number	Phase	Protocol Title
A012103	III	OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A012301	III	LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer
CCTG MA.39	III	Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
EA1211	II	Interim FDG-PET/CT for PreDICTing REsponse of HER2+ Breast Cancer to Neoadjuvant Therapy: DIRECT Trial
NRG-BR007	III	A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score \leq 18 Breast Cancer (DEBRA)
NRG-BR008	III	A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO*) *Her2 Radiation Optimization (HERO)
NRG-BR009	III	A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score \leq 25 (OFSET)
S2206	III	Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
S2212	III	Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
EAY191	Other	Molecular Analysis for Combination Therapy Choice (ComboMATCH)
EAY191-A3	II	Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial
EAY191-E5	II	A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial

This portfolio shows NCTN trials. For information about NCORP trials, please see: <https://ncorp.cancer.gov/find-a-study/>